RGD Reference Report - Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment.

Authors: Murdaca, G  Colombo, BM  Contini, P  Puppo, F 
Citation: Murdaca G, etal., J Interferon Cytokine Res. 2012 Jun;32(6):277-9. doi: 10.1089/jir.2011.0120. Epub 2012 Apr 5.
RGD ID: 8548821
Pubmed: PMID:22480318   (View Abstract at PubMed)
DOI: DOI:10.1089/jir.2011.0120   (Journal Full-text)

Tumor necrosis factor (TNF)-alpha plays a central role in psoriatic arthritis (PsA). A subgroup of patients with PsA do not respond to anti-TNF-alpha antibodies but respond to TNF receptor p75-Fc IgG fusion protein (etanercept), which also neutralizes lymphotoxin (LT)-alpha. It has been suggested that LT-alpha might be involved in the development of the disease. We determined LT-alpha serum levels in 15 PsA patients before (T0) and after 3, 6, 9, and 12 months of etanercept therapy (T3, T6, T9, and T12, respectively) and correlated them with their response to treatment. Bath Ankylosing Spondylitis Disease Activity Index, Psoriasis Area Severity Index, Disease Activity Score (DAS28), erythrocyte sedimentation rate (ESR), and C reactive protein (CRP) levels were assessed at the same time points. All patients showed a clinical response at T6, which persisted up to T12; ESR and CRP mean levels significantly decreased at T3 and remained within the normal range up to T12. LT-alpha levels significantly increased from T3 to T6 and returned to baseline levels at T12. Therefore, the LT-alpha serum levels do not seem to correlate with clinical and laboratory parameters of the response to etanercept in PsA patients. Further studies are required to better define the role of LT-alpha and LT-alpha blockade by etanercept in PsA patients.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
psoriatic arthritis treatmentIEP 8548821 RGD 
psoriatic arthritis treatmentISOLTA (Homo sapiens)8548821; 8548821 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Lta  (lymphotoxin alpha)

Genes (Mus musculus)
Lta  (lymphotoxin A)

Genes (Homo sapiens)
LTA  (lymphotoxin alpha)


Additional Information